The management of hyperthyroidism

New England Journal of Medicine

Volumn 330, Issue 24, 1994, Pages 1731-1738

  Wood, Alastair J j ^a   Franklyn, Jayne A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC BETA ANTAGONISTS; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; RADIOACTIVE IODINE; ANTITHYROID AGENT; ATENOLOL; CARBIMAZOLE; GLUCOCORTICOID; IOPANOIC ACID; IOPODATE SODIUM; LIOTHYRONINE; LITHIUM CARBONATE; LUGOL; METOPROLOL; NADOLOL; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; PROPRANOLOL; PROPYLTHIOURACIL; SALICYLIC ACID DERIVATIVE; THIAMAZOLE; THYROTROPIN; THYROXINE; WARFARIN;

HUMAN; HYPERTHYROIDISM; REVIEW; THYROID DISEASE; THYROIDECTOMY; TREATMENT OUTCOME; AGRANULOCYTOSIS; CLINICAL TRIAL; DRUG ERUPTION; EYE DISEASE; GRAVES DISEASE; HYPOTHYROIDISM; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; ORAL DRUG ADMINISTRATION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PRURITUS; RECTAL DRUG ADMINISTRATION; SUBTOTAL THYROIDECTOMY; TERATOGENICITY; THYROID ADENOMA; THYROID CANCER; THYROID CRISIS; THYROIDITIS; TOXIC GOITER;

ADRENERGIC BETA-ANTAGONISTS; HUMAN; HYPERTHYROIDISM; IODINE RADIOISOTOPES; SUPPORT, NON-U.S. GOV'T; THYROID DISEASES; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 0028775261     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199406163302407     Document Type: Review

References (89)

1. Tunbridge WMG, Evered DC, Hall R, The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7: 481-493
2. Wartofsky L, Glinoer D, Solomon B, Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan and the United States. Thyroid 1991; 1: 129-135
3. Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA 1990; 263: 1529-1532
4. Ruiz M, Rajatanavin R, Young RA, Familial dysalbuminemic hyperthyroxinemia: a syndrome that can be confused with thyrotoxicosis. N Engl J Med 1982; 306: 635-639
5. Sakata S, Nakamura S, Miura K Autoantibodies against thyroid hormones or iodothyronine: implications in diagnosis, thyroid function, treatment, and pathogenesis. Ann Intern Med 1985; 103: 579-589
6. Ross DS, Daniels GH, Gouveia D The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. J Clin Endocrinol Metab 1990; 71: 764-769
7. Nicoloff JT, Spencer CA The use and misuse of the sensitive thyrotropin assays. J Clin Endocrinol Metab 1990; 71: 553-558
8. Davies PH, Franklyn JA The effects of drugs on tests of thyroid function. Eur J Clin Pharmacol 1991; 40: 439-451
9. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991; 34: 77-83
10. Reinwein D, Benker G, Konig MP, Pinchera A, Schatz H, Schleusener A The different types of hyperthyroidism in Europe: results of a prospective survey of 924 patients. J Endocrinol Invest 1988; 11: 193-200
11. Learoyd DL, Fung HYM, McGregor AM Postpartum thyroid dysfunction. Thyroid 1992; 2: 73-80
12. Totterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N Engl J Med 1987; 316: 15-22
13. Kampmann JP, Hansen JM Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet 1981; 6: 401-428
14. Barnes HV, Bledsoe T A simple test for selecting the thioamide schedule in thyrotoxicosis. J Clin Endocrinol Metab 1972; 35: 250-255
15. Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari Y, Fujishima M Reevaluation of the effects of methylmercaptomidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1987; 65: 719-723
16. Franklyn JA, Black EG, Wilson EM, Davis JRE, Sheppard MC Limitations of a sensitive assay for thyrotropin in managing patients with thyroid disease. Clin Chem 1988; 34: 991-992
17. Dahlberg PA, Karlsson FA, Lindstrom B, Wide L Studies of thyroid hormone and methimazole levels in patients with Graves' disease on a standardized anti-thyroid drug regimen. Clin Endocrinol (Oxf) 1981; 14: 555-562
18. Mashio Y, Beniko M, Ikota A, Mizumoto H, Kunita H Treatment of hyperthyroidism with a small single daily dose of methimazole. Acta Endocrinol (Copenh) 1988; 119: 139-144
19. Reinwein D, Benker G, Lazarus JH, Alexander WD A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. J Clin Endocrinol Metab 1993; 76: 1516-1521
20. Cooper DS, Goldminz D, Levin AA, Agranulocytosis associated with antithyroid drugs: effects of patient age and drug dose. Ann Intern Med 1983; 98: 26-29
21. Tamai H, Takaichi Y, Morita T, Methimazole-induced agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol (Oxf) 1989; 30: 525-530
22. Tajiri J, Noguchi S, Murakami T, Murakami N Antithyroid drug-induced agranulocytosis: the usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150: 621-624
23. Liaw Y-F, Huang M-J, Fan K-D, Li K-L, Wu S-S, Chen T-J Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism: a cohort study. Ann Intern Med 1993; 118: 424-428
24. Greer MA, Kammer H, Bouma DJ Short-term antithyroid drug therapy for the thyrotoxicosis of Graves's disease. N Engl J Med 1977; 297: 173-176
25. Sugrue D, McEvoy M, Feely J, Drury MI Hyperthyroidism in the land of Graves: results of treatment by surgery, radio-iodine and carbimazole in 837 cases. Q J Med 1980; 49: 51-61
26. Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Clin Endocrinol (Oxf) 1989; 31: 209-218
27. Teng CS, Yeung RTT Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drugs and its relationship to relapse: a prospective study. J Clin Endocrinol Metab 1980; 50: 144-147
28. Allannic H, Fauchet R, Orgiazzi J, Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70: 675-679
29. Wilson R, McKillop JH, Henderson N, Pearson DW, Thomson JA The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease. Clin Endocrinol (Oxf) 1986; 25: 151-156
30. Weetman AP, Ratanachaiyavong S, Middleton GW, Prediction of outcome in Graves' disease after carbimazole treatment. Q J Med 1986; 59: 409-419
31. Schleusener H, Schwander J, Fischer C, Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 1989; 120: 689-701 [Erratum, Acta Endocrinol (Copenh) 1989;121:304.]
32. Young ET, Steel NR, Taylor JJ, Prediction of remission after antithyroid drug treatment in Graves' disease. Q J Med 1988; 66: 175-189
33. Tamai H, Nakagawa T, Fukino O, Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy. Ann Intern Med 1980; 92: 448-490
34. Lippe BM, Landaw EM, Kaplan SA Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987; 64: 1241-1245
35. Wise PH, Marion M, Pain RW Single dose, “block-replace” drug therapy in hyperthyroidism. BMJ 1973; 4: 143-145
36. Hashizume K, Ichikawa K, Sakurai A, Administration of thyroxine in treated Graves' disease: effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-953
37. McDevitt DG, Nelson JK Comparative trial of atenolol and propranolol in hyperthyroidism. Br J Clin Pharmacol 1978; 6: 233-237
38. Murchison LE, How J, Bewsher PD Comparison of propranolol and metoprolol in the management of hyperthyroidism. Br J Clin Pharmacol 1979; 8: 581-587
39. Peden NR, Isles TE, Stevenson IH, Crooks J Nadolol in thyrotoxicosis. Br J Clin Pharmacol 1982; 13: 835-840
40. Philippou G, Koutras DA, Piperingos G, Souvatzoglou A, Moulopoulos SD The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. Clin Endocrinol (Oxf) 1992; 36: 573-578
41. Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) 1991; 34: 71-76
42. Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med 1984; 311: 426-432
43. Holm L-E, Lundell G, Israelsson A, Dahlqvist I Incidence of hypothyroidism long after iodine-131 therapy for hyperthyroidism. J Nucl Med 1982; 23: 103-107
44. Roudebush CP, Hoye KE, DeGroot LJ Compensated low-dose 131I therapy of Graves' disease. Ann Intern Med 1977; 87: 441-443
45. Lowdell CP, Dobbs HJ, Spathis GS, McCready VR, Cosgrove DO, Harmer CL Low-dose 131I in treatment of Graves' disease. J R Soc Med 1985; 78: 197-202
46. Watson AB, Brownlie BEW, Frampton CM, Turner JG, Rogers TGH Outcome following standardized 185 MBq dose 131I therapy for Graves' disease. Clin Endocrinol (Oxf) 1988; 28: 487-496
47. Nordyke RA, Gilbert FI Jr Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991; 32: 411-416
48. Turner J, Sadler W, Brownlie B, Rogers T Radioiodine therapy for Graves' disease: multivariate analysis of pretreatment parameters and early outcome. Eur J Nucl Med 1985; 11: 191-193
49. Kendall-Taylor P, Keir MJ, Ross WM Ablative radioiodine therapy for hyperthyroidism: long term follow up study. BMJ 1984; 289: 361-363
50. Ross DS, Neer RM, Ridgway EC, Daniels GH Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987; 82: 1167-1170
51. Franklyn JA, Sheppard MC Thyroxine replacement treatment and osteoporosis. BMJ 1990; 300: 693-694
52. Leese GP, Jung RT, Guthrie C, Waugh N, Browning MCK Morbidity in patients on L-thyroxine: a comparison of those with normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 1992; 37: 500-503
53. Sawin CT, Geller A, Hershman JM, Castelli W, Bacharach P The aging thyroid: the use of thyroid hormone in older persons. JAMA 1989; 261: 2653-2655
54. Goolden AWG, Stewart JSW Long-term results from graded low-dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1986; 24: 217-222
55. Hardisty CA, Jones SJ, Hedley AJ, Munro DS, Bewsher PD, Weir RD Clinical outcome and costs of care in radioiodine treatment of hyperthyroidism. J R Coll Physicians Lond 1990; 24: 36-42
56. MacFarlane IA, Shalet SM, Beardwell CG, Khara JS Transient hypothyroidism after iodine-131 treatment for thyrotoxicosis. BMJ 1979; 2: 421-421
57. Hennemann G, Krenning EP, Sankaranarayanan K Place of radioactive iodine in treatment of thyrotoxicosis. Lancet 1986; 1: 1369-1372
58. Davies PH, Franklyn JA, Daykin J, Sheppard MC The significance of TSH values measured in a sensitive assay in the follow-up of hyperthyroid patients treated with radioiodine. J Clin Endocrinol Metab 1992; 74: 1189-1194
59. Velkeniers B, Cytryn R, Vanhaelst L, Jonckheer MH Treatment of hyperthyroidism with radioiodine: adjunctive therapy with antithyroid drugs reconsidered. Lancet 1988; 1: 1127-1129
60. Sridama V, DeGroot LJ Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 1989; 87: 70-73
61. Tallstedt L, Lundell G, Torring O, Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992; 326: 1733-1738
62. Spencer RP, Chapman CN, Rao H Thyroid carcinoma after radioiodine therapy for hyperthyroidism: analysis based on age, latency, and administered dose of I-131. Clin Nucl Med 1983; 8: 216-219
63. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974; 38: 976-998
64. Holm L-E, Hall P, Wiklund K, Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991; 83: 1072-1077
65. Hall P, Boice JD Jr, Berg G, Leukaemia incidence after iodine-131 exposure. Lancet 1992; 340: 1-4
66. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, Ridgway EC Radioactive iodine therapy and breast cancer: a follow-up study of hyperthyroid women. Am J Epidemiol 1988; 127: 969-980
67. Stoffer SS, Hamburger JI Inadvertent 131I therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med 1976; 17: 146-149
68. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 1976; 17: 460-464
69. Robertson JS, Gorman CA Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism. J Nucl Med 1976; 17: 826-835
70. Toft AD, Irvine WJ, Sinclair I, McIntosh D, Seth J, Cameron EHD Thyroid function after surgical treatment of thyrotoxicosis: a report of 100 cases treated with propranolol before operation. N Engl J Med 1978; 298: 643-647
71. Feek CM, Sawers JSA, Irvine WJ, Beckett GJ, Ratcliffe WA, Toft AD Combination of potassium iodide and propranolol in preparation of patients with Graves' disease for thyroid surgery. N Engl J Med 1980; 302: 883-885
72. Sawyers JL, Martin CE, Byrd BF Jr, Rosenfeld L Thyroidectomy for hyperthyroidism. Ann Surg 1972; 175: 939-947
73. Blichert-Toft M, Jorgensen SJ, Hansen JB, Watt-Boolsen S, Christiansen C, Ibsen J Long-term observation of thyroid function after surgical treatment of thyrotoxicosis. Acta Chir Scand 1977; 143: 221-227
74. Toft AD, Kellett HA, Sawers JSA, What is the significance of raised plasma TSH levels after thyroid surgery? Scott Med J 1982; 27: 216-219
75. Evered D, Young ET, Tunbridge WMG, Thyroid function after subtotal thyroidectomy for hyperthyroidism. BMJ 1975; 1: 25-27
76. Scott GR, Forfar JC, Toft AD Graves' disease and atrial fibrillation: the case for even higher doses of therapeutic iodine-131. BMJ 1984; 289: 399-400
77. Petersen P, Hansen JM Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988; 19: 15-18
78. Hamburger JI Solitary autonomously functioning thyroid lesions: diagnosis, clinical features and pathogenetic considerations. Am J Med 1975; 58: 740-748
79. Molnar GD, Wilbur RD, Lee RE, Woolner LB, Keating FR Jr On the hyperfunctioning solitary thyroid nodule. Mayo Clin Proc 1965; 40: 665-684
80. Ng Tang Fui SC, Maisey MN Standard dose 131I therapy for hyperthyroidism caused by autonomously functioning thyroid nodules. Clin Endocrinol (Oxf) 1979; 10: 69-77
81. Ross DS, Ridgway EC, Daniels GH Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. Ann Intern Med 1984; 101: 488-490
82. Goldstein R, Hart IR Follow-up of solitary autonomous thyroid nodules treated with 131I. N Engl J Med 1983; 309: 1473-1476
83. Othman S, Phillips DIW, Parkes AB, A long-term follow-up of postpartum thyroiditis. Clin Endocrinol (Oxf) 1990; 32: 559-564
84. Kampmann JP, Johansen K, Hansen JM, Helweg J Propylthiouracil in human milk: revision of a dogma. Lancet 1980; 1: 736-737
85. Momotani N, Yamashita R, Yoshimoto M, Noh J, Ishikawa N, Ito K Recovery from foetal hypothyroidism: evidence for the safety of breast-feeding while taking propylthiouracil. Clin Endocrinol (Oxf) 1989; 31: 591-595
86. Momotani N, Noh J, Oyanagi H, Ishikawa N, Ito K Antithyroid drug therapy for Graves' disease during pregnancy: optimal regimen for fetal thyroid status. N Engl J Med 1986; 315: 24-28
87. Amino N, Kuro R, Tanizawa O, Changes of serum anti-thyroid antibodies during and after pregnancy in autoimmune thyroid diseases. Clin Exp Immunol 1978; 31: 30-37
88. Roti E, Robuschi G, Gardini E, Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. Clin Endocrinol (Oxf) 1988; 28: 305-314
89. Libert F, Lefort A, Gerard C, Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Commun 1989; 165: 1250-1255